Johnson & Johnson Beats Second-Quarter Expectations
Johnson & Johnson reported second-quarter results that exceeded Wall Street forecasts. However, the company’s shares fell by around 1% in premarket trading on Wednesday.
The healthcare group posted adjusted earnings of $2.90 per share. This was four cents above the analyst consensus estimate of $2.86.
Quarterly revenue reached $25.31 billion, also beating the $25.02 billion forecast. Sales increased by 6.6% from $23.74 billion during the same quarter last year.
J&J Raises Its 2026 Earnings Outlook
Johnson & Johnson increased its full-year adjusted earnings guidance following the stronger-than-expected results.
The company now expects adjusted earnings per share of between $11.60 and $11.75. The midpoint of $11.68 is above the current Wall Street estimate of $11.58.
Revenue for 2026 is projected to range from $100.8 billion to $101.4 billion. The midpoint of $101.1 billion came in slightly above the analyst consensus of $101.06 billion.
Innovation and Product Pipeline Support Growth
Chief Executive Joaquin Duato said the results highlighted the strength of Johnson & Johnson’s innovation, diversified portfolio, and product pipeline.
He added that the company continues to develop treatments aimed at addressing some of the most challenging healthcare conditions worldwide.
Innovative Medicine Segment Leads Sales Growth
Johnson & Johnson’s Innovative Medicine division remained the main driver of growth during the quarter.
Worldwide operational sales in the segment increased by 6.8%. Oncology treatments such as DARZALEX, CARVYKTI, TECVAYLI, and RYBREVANT delivered strong performances.
Growth was also supported by TREMFYA in immunology, along with SPRAVATO and CAPLYTA in neuroscience.
However, weaker sales of STELARA and REMICADE partially offset those gains.
MedTech Revenue Also Moves Higher
The MedTech business recorded operational sales growth of 3.6%.
Demand increased for wound-closure products, biosurgery solutions, electrophysiology equipment, and Shockwave products.
The performance showed that Johnson & Johnson continued to benefit from growth across both its pharmaceutical and medical technology businesses.
U.S. and International Sales Increase
Sales in the United States climbed by 7.3% to $14.53 billion.
International revenue increased by 5.7% to $10.78 billion, showing broad growth across the company’s major geographic markets.
GAAP Earnings Edge Lower
Johnson & Johnson reported GAAP earnings of $2.27 per share for the quarter.
That figure was slightly below the $2.29 per share recorded during the same period last year.
Despite the small decline in reported earnings, the company generated approximately $8.7 billion in free cash flow during the first half of the year.
Why Johnson & Johnson Shares Dipped
Although Johnson & Johnson exceeded revenue and adjusted earnings forecasts, the positive results were not enough to lift the stock in premarket trading.
Investors may have already priced in a strong quarter, while the limited increase in full-year revenue guidance may have reduced enthusiasm.
Nevertheless, the company delivered solid sales growth, raised its earnings outlook, and continued to benefit from momentum across oncology, immunology, neuroscience, and medical technology.
